Summary
As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA. The biosimilars market continues to maintain momentum as we head into 2020, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings. This conferences allows attendees to join the “who’s who” of the biosimilars and innovator biologics industries as they gather for ACI’s 2020 Summit on Biosimilars & Innovator Biologics, and contemplate these and other probing questions.